BridgIT, a New Tool for Orphan and Novel Enzyme Reactions

Effective protein engineering can give us control over the generated products inside a cell. However, for many of the biochemical reactions responsible for these products, we don't we don't know the specific protein- or enzyme-producing gene responsible. These reactions are called "orphan" and have become a big problem for protein engineers.

Moreover, software that predicts novel, hypothetical biochemical reactions - a common tool for modern biochemists and synthetic biologists - cannot assign potential genes to them, meaning that there are no recorded DNA sequences that scientists can tweak to change protein or enzyme production. And to further complicate matters, there are also many "orphan" metabolic enzymes whose particular reaction is unknown, thus leaving important gaps in our maps of metabolic networks and pathways.

In short, finding which gene(s) correspond to the enzyme/protein(s) that catalyze an orphan or novel, hypothetical reaction has grown into a critical issue for applications ranging from biotechnology to medicine.

Fortunately, chemical engineers from the lab of Vassily Hatzimanikatis at EPFL have found a solution. The group developed a new computational method and online tool, called "BridgIT", to identify candidate genes and catalyzing proteins for orphan and novel, hypothetical reactions. All BridgIT needs to know is the four connecting bonds around the atoms of the reactive sites, and it can correctly annotate proteins for 93% of analyzed enzymatic reactions. This percentage rose to almost 100% when seven connecting bonds were included.

To test BridgIT's accuracy, the researchers pitted it against databases of reactions that were once orphan but have now been assigned to genes and enzymes - basically, reactions that have become "non-orphan". BridgIT predicted the exact or a highly related enzyme for 211 out of 234 reactions (>90%). And for hypothetical reactions that were once novel and have since been assigned enzymes, BridgIT found the exact enzymes for 334 out of 379 reactions (>88%).

The authors write: "BridgIT... will allow researchers to fill the knowledge gaps in metabolic networks and will act as a starting point for designing novel enzymes to catalyze non-natural transformations."

Noushin Hadadi, Homa MohammadiPeyhani, Ljubisa Miskovic, Marianne Seijo, Vassily Hatzimanikatis.
Enzyme annotation for orphan and novel reactions using knowledge of substrate reactive sites.
PNAS 25 March 2019. doi: 10.1073/pnas.1818877116.

Most Popular Now

MRI Predict Intelligence Levels in Child…

A group of researchers from the Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) took 4th place in the international MRI-based adolescent intelligence prediction competition. For the first...

CAD4TB: Artificial Iintelligence for Tub…

Is it possible to screen thousands of people for tuberculosis using artificial intelligence in a country where internet barely exists? It is with CAD4TB. As of October, this innovative software...

Pros and Cons of Mommy Mobile Apps

Mobile phone apps are increasingly being used to support breastfeeding decisions - sometimes at a cost, a Flinders University study indicates. The objective approach of most infant feeding (IF) apps...

Finally, Machine Learning Interprets Gen…

In this age of "big data," artificial intelligence (AI) has become a valuable ally for scientists. Machine learning algorithms, for instance, are helping biologists make sense of the dizzying number...

Philips Expands its Range of Consumer-Fo…

At CES 2020, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its expansion of personalized consumer health solutions that help shape the industry of...

Gloucestershire Hospitals Announce Signi…

Gloucestershire Hospitals NHS Foundation Trust has gone live with the first elements of its Allscripts Sunrise electronic patient record just five months after signing a contract with the company. The trust...

Bayer and Exscientia Collaborate to Leve…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary...

A Better Testing Method for Patients wit…

Parkinson's disease is a neurodegenerative disorder that manifests through symptoms such as tremor, slow movements, limb rigidity and gait and balance problems. As such, nearly all diagnostic testing revolves around...

Artificial Intelligence (AI) can Detect …

A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has...